State Street’s Impact BioMedical IBO Stock Holding History

State Street’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Hold	607,897	–	–	﹤0.01%	3733
2026 Q1	$365K	Buy	607,897 +596,100	+5,053%	+$298K	﹤0.01%	3731
2025 Q4	$5.96K	Hold	11,797	–	–	﹤0.01%	4280
2025 Q3	$7.84K	Hold	11,797	–	–	﹤0.01%	4273
2025 Q2	$7.63K	Hold	11,797	–	–	﹤0.01%	4247
2025 Q1	$10.3K	Buy	11,797 +626	+6%	+$1.08K	﹤0.01%	4252
2024 Q4	$16.2K	Buy	+11,171	New	+$23.2K	﹤0.01%	4250

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

State Street's IBO Position: Q2 2026 in Review

State Street held its Impact BioMedical (IBO) position steady in Q2 2026 at 607,897 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #3733.

State Street first reported a position in IBO in Q4 2024 and has held it in 7 quarters since. The position peaked at $365K in Q1 2026. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

State Street held 607,897 shares of Impact BioMedical worth $280K as of Q2 2026.
State Street left its Impact BioMedical share count unchanged in Q2 2026.
Impact BioMedical made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3733 holding.
State Street first reported a position in Impact BioMedical in Q4 2024 and has held it in 7 quarters since.
State Street's Impact BioMedical position peaked at $365K in Q1 2026.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.